文献速递神经肿瘤

我如何治疗复发性儿童高级别胶质瘤(pHGG):一项欧洲范围的调查研究

How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.
PubMed 文献 · J Neurooncol · 2023-02-01

该研究通过基于网络的问卷,调查了22个欧洲国家139名儿童神经肿瘤学临床医生对四例复发性/进展性儿童高级别胶质瘤病例的治疗选择。结果显示,专家倾向于联合传统多模式治疗(包括再照射)与基于分子遗传学发现的靶向治疗,并建议开展国际合作试验以获取有效临床数据。

要点

  • 在四例复发性/进展性pHGG病例中,多数受访者倾向于进一步肿瘤学治疗,一例症状明显者选择姑息治疗。
  • 根据病例不同,8-92%的受访者会启动再切除(优选半球pHGG),并结合分子诊断。
  • 所有病例中55-77%推荐(再)照射,优选局部放疗>20 Gy;多数受访者会参与临床试验并使用靶向治疗(79-99%)。

核心结论

  • 专家在每个病例中都会结合传统多模式治疗概念(包括再照射)与基于分子遗传学发现的靶向治疗。
  • 针对特定亚组、结合(化疗)治疗骨架与靶向治疗的国际合作试验可能有助于获得有效临床数据并改善复发性/进展性pHGG患儿的治疗。

研究设计与样本

  • 通过基于网络的问卷,调查SIOPE-BTG和GPOH成员对四例复发性/进展性儿童高级别胶质瘤病例治疗选择的意见。
  • 共139名来自22个欧洲国家的具有儿童神经肿瘤学经验的临床医生参与调查。

主要发现

  • 在四例病例中,三例多数受访者倾向于进一步肿瘤学治疗,一例症状明显者选择姑息治疗。
  • 根据病例不同,8-92%的受访者会启动再切除(优选半球pHGG),并结合分子诊断。
  • 所有病例中55-77%推荐(再)照射,优选局部放疗>20 Gy。
  • 多数受访者会参与临床试验并使用靶向治疗(79-99%),具体取决于分子遗传学发现:BRAF改变者64-88%使用BRAF/MEK抑制剂;EGFR过表达者46%使用抗EGFR治疗;CDKN2A缺失者18%使用CDK抑制剂;SMARCB1缺失者12%使用EZH2抑制剂。
  • 31-72%的受访者会给予化疗(CCNU 17%;PCV 8%;替莫唑胺19%;口服依托泊苷/曲磷胺8%),20-69%建议免疫治疗(检查点抑制剂30%;肿瘤疫苗16%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As there is no standard of care treatment for recurrent/progressing pediatric high-grade gliomas (pHGG), we aimed to gain an overview of different treatment strategies. METHODS: In a web-based questionnaire, members of the SIOPE-BTG and the GPOH were surveyed on therapeutic options in four case scenarios (children/adolescents with recurrent/progressing HGG). RESULTS: 139 clinicians with experience in pediatric neuro-oncology from 22 European countries participated in the survey. Most respondents preferred further oncological treatment in three out of four cases and chose palliative care in one case with marked symptoms. Depending on the case, 8-92% would initiate a re-resection (preferably hemispheric pHGG), combined with molecular diagnostics. Throughout all case scenarios, 55-77% recommended (re-)irradiation, preferably local radiotherapy > 20 Gy. Most respondents would participate in clinical trials and use targeted therapy (79-99%), depending on molecular genetic findings (BRAF alterations: BRAF/MEK inhibitor, 64-88%; EGFR overexpression: anti-EGFR treatment, 46%; CDKN2A deletion: CDK inhibitor, 18%; SMARCB1 deletion: EZH2 inhibitor, 12%). 31-72% would administer chemotherapy (CCNU, 17%; PCV, 8%; temozolomide, 19%; oral etoposide/trofosfamide, 8%), and 20-69% proposed immunotherapy (checkpoint inhibitors, 30%; tumor vaccines, 16%). Depending on the individual case, respondents would also include bevacizumab (6-18%), HDAC inhibitors (4-15%), tumor-treating fields (1-26%), and intraventricular chemotherapy (4-24%). CONCLUSION: In each case, experts would combine conventional multimodal treatment concepts, including re-irradiation, with targeted therapy based on molecular genetic findings. International cooperative trials combining a (chemo-)therapy backbone with targeted therapy approaches for defined subgroups may help to gain valid clinical data and improve treatment in pediatric patients with recurrent/progressing HGG.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Perwein T, Giese B, Nussbaumer G, et al. How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study. J Neurooncol. 2023. PMID: 36720762. doi:10.1007/s11060-023-04241-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。